News | Structural Heart | April 25, 2024

Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement

First FDA approved transcatheter therapy for patients with tricuspid regurgitation

First FDA approved transcatheter therapy for patients with tricuspid regurgitation

April 25, 2024 — Atlantic Health System’s Morristown Medical Center treated the first patient in New Jersey using Edwards Lifesciences EVOQUE tricuspid valve replacement, the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for improving the health status in patients with symptomatic severe TR despite optimal medical therapy, and for whom tricuspid valve replacement is deemed appropriate by a heart care team. According to National Institutes of Health an estimated 1.6 million people in the U.S. have been diagnosed with TR.

“Until now, there was no available transcatheter treatment options for patients with tricuspid valve disease,” said Robert Kipperman, MD, interventional cardiologist and structural heart disease specialist at Gagnon Cardiovascular Institute’s Valve Center at Morristown Medical Center, part of Atlantic Health System. “We are thrilled to have a new transcatheter valve option which allows patients to feel significantly better by alleviating symptoms such as shortness of breath and can help improve the patients’ quality of life.”

About Atlantic Health System

Atlantic Health System is at the forefront of medicine, setting standards for quality health care in New Jersey, Pennsylvania and the New York metropolitan area. Powered by a workforce of 20,000 team members and 5,440 affiliated physicians dedicated to building healthier communities, Atlantic Health System serves more than half of the state of New Jersey including 14 counties and 7.5 million people. The not-for-profit system offers more than 550 sites of care, including its seven hospitals: Morristown Medical Center in Morristown, NJ, Overlook Medical Center in Summit, NJ, Newton Medical Center in Newton, NJ, Chilton Medical Center in Pompton Plains, NJ, Hackettstown Medical Center in Hackettstown, NJ, Goryeb Children’s Hospital in Morristown, NJ, Atlantic Rehabilitation Institute in Madison, NJ and through its partnership with CentraState Healthcare System in Freehold, NJ.

The system includes Atlantic Medical Group, part of a physician enterprise that makes up one of the largest multispecialty practices in New Jersey with more than 1,600 physicians and advance practice providers. Joined with Atlantic Accountable Care Organization and Optimus Healthcare Partners they form part of Atlantic Alliance, a Clinically Integrated Network of more than 2,500 health care providers throughout northern and central NJ.

Atlantic Health System provides care for the full continuum of health care needs through 24 urgent care centers, Atlantic Visiting Nurse and Atlantic Anywhere Virtual Visits. Facilitating the connection between these services on both land and air is the transportation fleet of Atlantic Mobile Health.Atlantic Health System leads the Healthcare Transformation Consortium, a partnership of six regional hospitals and health systems dedicated to improving access and affordability and is a founding member of the PIER Consortium – Partners in Innovation, Education, and Research – a streamlined clinical trial system that will expand access to groundbreaking research across five health systems in the region.

Atlantic Health System has a medical school affiliation with Thomas Jefferson University and is home to the regional campus of the Sidney Kimmel Medical College at Morristown and Overlook Medical Centers and is the official health care partner of the New York Jets.

For more information: www.atlantichealth.org

 

Related Content: 

Edwards Evoque Transcatheter Tricuspid Valve Replacement System Receives CE Mark

Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement 

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients 

Edwards LifeSciences Reports Positive Clinical Updates on its Transcatheter Mitral and Tricuspid Valves 

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy Earns FDA Approval for Tricuspid Valve


Related Content

News | FDA

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
Subscribe Now